Orchestra BioMed Announces Virtue SAB Presentation at TCT 2026

Presentation will highlight Virtue SAB's fundamentally different approach of infusing a large liquid volume of proprietary extended-release SirolimusEFR™ directly into and throughout the vessel wall. Virtue SAB's mechanism is designed to achieve sustained, transmural sirolimus tissue levels substantially exceeding those achieved by drug-eluting stents and drug-coated balloons.

GlobeNewsWire • 9 hours ago

American Century Equity Income Fund Q3 2026 Portfolio Activity

Becton Dickinson and Co. reported strong quarterly results, improved cash flow and a higher earnings outlook. Kimberly-Clark's shares declined after management lowered its growth outlook amid softer demand trends and disruptions in China. The portfolio's underweight position in Apple relative to the benchmark detracted as optimism around its ecosystem and artificial intelligence opportunities supported the stock during the period.

Seeking Alpha • 13 hours ago

Medtronic: Broader Growth, Attractive Valuation

Medtronic is rated Buy, trading at a 20.8% P/E discount to sector median, with new products driving broader growth post-MiniMed separation. Pulsed field ablation (PFA) and enabling technologies in Cardiovascular and Spine divisions are key growth engines, with strong Q1 FY2027 results across all segments. Q1 FY2027 organic revenue grew ~7% (adjusted for extra week), but margin expansion remains limited; management is focused on translating growth into durable earnings leverage.

Seeking Alpha • Oct 28, 2026

Medtronic Quietly Raised Its Dividend Again. Is It a Buy for Income Investors?

Medtronic just extended a nearly half-century dividend streak, but its raise barely outpaces inflation while rivals like Abbott and J&J grow payouts far faster.

24/7 Wall Street • Oct 27, 2026

Medtronic Has Raised Its Dividend for 49 Years. These 2 Rivals Have Even Longer Streaks

Medtronic's 49-year dividend streak sounds impressive until you meet the two medical device rivals that have been raising payouts even longer, and the differences in yield, valuation, and balance sheet strength could reshape how you think about income investing in

24/7 Wall Street • Oct 27, 2026

Medtronic announces positive results from real-world registries for the Sphere-9™ catheter and PulseSelect™ PFA System at APHRS 2026

Global APEX and REAL PULSE Registry analyses report strong safety and procedural outcomes across atrial and ventricular arrhythmias Medtronic continues to strengthen its position in cardiac ablation, building on a legacy of innovation in electrophysiology GALWAY, Ireland, Oct. 22, 2026 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced positive real-world registry results for the Affera™ Mapping and Ablation System with the Sphere-9™ Catheter and the PulseSelect™ Pulsed Field Ablation (PFA) System. The global registry analyses, presented at the Asia Pacific Heart Rhythm Society (APHRS) 2026 scientific meeting, evaluated prospectively enrolled patients with atrial fibrillation (AFib) and ventricular tachycardia (VT).

PRNewsWire • Oct 22, 2026

Orchestra BioMed to Host R&D Day Featuring Clinical Insights and Development Plans for AVIM Therapy and Virtue® SAB

NEW HOPE, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced it will host an R&D Day on November 12th, 2026, at 3:00pm ET in New York City.

GlobeNewsWire • Oct 22, 2026

Medtronic (MDT) Stock Dips While Market Gains: Key Facts

In the latest trading session, Medtronic (MDT) closed at $92.77, marking a -2.09% move from the previous day.

Zacks Investment Research • Oct 19, 2026

The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning

Rate and energy headlines have kept the broad market jumpy, yet one sector keeps finding buyers. Healthcare has led on days when the S&P 500 slipped, and the Nasdaq Biotechnology Index has pushed to record highs.

MarketBeat • Oct 19, 2026

Is it Apt to Retain Medtronic Stock in Your Portfolio Now?

MDT expands in cardiac ablation, robotics, hypertension and digital surgery, but tariff, inflation and currency risks are likely to pressure margins.

Zacks Investment Research • Oct 16, 2026